CoChat

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

Open access

Published version of a preprint

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Purpose: To investigate changes of peripheral blood biomarkers and their impact on clinical outcome following treatment with ipilimumab in advanced melanoma patients. Experimental Design: Changes in blood counts and the frequency of circulating immune cell populations analyzed by flow cytometry were investigated in 82 patients to compare baseline values with different time-points after starting ipilimumab. Endpoints were overall survival (OS) and best clinical response. Statistical calculations were done by Wilcoxon-matched pairs tests, Fisher exact test, Kaplan–Meier analysis, and Cox regression analysis. Results: Increases in absolute lymphocyte counts (ALC) 2 to 8 weeks (P = 0.003) and in percentages of CD4+ and CD8+ T cells 8 to 14 weeks (P = 0.001 and P = 0.02) after the first dose of ipilimumab were correlated with improved survival. These associations did not meet significance criteria, when conservatively adjusted for multiple testing, but were additionally correlated with clinical responses (all P < 0.05). However, validation is required. Increases in all three factors were observed in 36% of patients, who had a favorable outcome and survival probabilities of 93.3% and 63.8% at 12 and 24 months, respectively. A partial or complete response was observed in 71% of these patients compared with only 8% in patients with decreases in ≥1 of the 3 factors, respectively. Changes of regulatory T cells or myeloid-derived suppressor cells were not associated with OS. Conclusions: Increases of ALC observed 2 to 8 weeks after initiation of ipilimumab and delayed increases in CD4+ and CD8+ T cells reflect changes associated with positive outcome. These changes represent surrogate marker candidates and warrant further validation. Clin Cancer Res; 22(19); 4848–58. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-0249

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 180

Metadata

Authors
Martens, A., Wistuba-Hamprecht, K., Yuan, J., Postow, M. A., Wong, P., Capone, M., Madonna, G., Khammari, A., Schilling, B., Sucker, A., Schadendorf, D., Martus, P., Dreno, B., Ascierto, P. A., Wolchok, J. D., Pawelec, G., Garbe, C., & Weide, B.
Affiliations
  • Universitätsklinikum Tübingen (DE)
  • 1Department of Dermatology, University Medical Center, Tübingen, Germany.
  • Memorial Sloan Kettering Cancer Center (US)
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
  • Inserm (FR)
  • Essen University Hospital (DE)
  • University of Tübingen (DE)
  • 6Department of Oncodermatology, INSERM Research Unit 892, University Hospital, Nantes, France.
Corresponding author
Weide, Benjamin
Venue
Clinical Cancer Research
Published
2016-10-01
Volume
22
Issue
19
Pages
4848-4858
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2392329487
Cited by
180
References
50
Citations by year
2026: 2 · 2025: 12 · 2024: 22 · 2023: 16 · 2022: 16 · 2021: 23 · 2020: 24 · 2019: 11 · 2018: 21 · 2017: 21 · 2016: 11
FWCI
11.49
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • HAL (submittedVersion)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
Funders
Bristol-Myers Squibb EU Seventh Framework Programme (305309)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
ipilimumab, advanced melanoma, absolute lymphocyte count, CD4+ T cells, CD8+ T cells, peripheral blood T cells, predictive biomarkers, overall survival, clinical response, immune checkpoint inhibitors, regulatory T cells, myeloid-derived suppressor cells
MeSH terms
Antineoplastic Agents, Immunological, Ipilimumab, Adult, Aged, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Biomarkers, Tumor, CD4-Positive T-Lymphocytes, Proportional Hazards Models, CD8-Positive T-Lymphocytes, Lymphocyte Count, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-0249
The paper
Martens, A., Wistuba-Hamprecht, K., Yuan, J., Postow, M. A., Wong, P., Capone, M., Madonna, G., Khammari, A., Schilling, B., Sucker, A., Schadendorf, D., Martus, P., Dreno, B., Ascierto, P. A., Wolchok, J. D., Pawelec, G., Garbe, C., & Weide, B. (2016). Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-0249

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.